With data from a second phase 3 trial, AstraZeneca has finally convinced FDA regulators that its new COPD offering deserves a place on the U.S. market just as a competitor from GlaxoSmithKline does.
WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from the Phase III KALOS and LOGOS trials in patients with uncontrolled asthma showed that AstraZeneca ...
Breztri can cost around $400 without insurance. Medicare drug plans may cover inhalers for COPD, including drugs like Breztri, but specific coverage and cost depend on the exact plan. Breztri ...
(The Hill) — Drugmaker AstraZeneca will cap out-of-pocket costs at $35 for all its inhaler products, the company announced Monday. The cap is effective June 1 and will apply to the company’s entire ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results